Menu

Report Library

View More

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
7/1/25 Beckley BPL-003 for Major Depressive Disorder (MDD) Subscribers Only Subscribers Only Subscribers Only
6/30/25 Arcturus (ARCT) LUNAR-OTC for Ornithine Transcarbamylase (OTC) Deficiency Subscribers Only Subscribers Only Subscribers Only
6/30/25 Amgen (AMGN) Bemarituzumab for Gastric Cancer Subscribers Only Subscribers Only Subscribers Only
6/26/25 Abbisko Therapeutics ABSK011 for Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) Subscribers Only Subscribers Only Subscribers Only
6/26/25 Altimmune (ALT) Pemvidutide for Non-Alcoholic Steatohepatitis (NASH) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
04/01/2025 Subscribers Only Subscribers Only Company - Divestment/Spinoff
04/24/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
05/20/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
05/22/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/02/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update